Global D has developed an zygomatic implant prosthetic system (ZygoFixU range): zygomatic implants, prosthetic parts and associated instruments. These devices have a design similar to other zygomatic implants on the market and are therefore not innovative. These non-CE marked devices are assessed during investigation 2302-G-ZYGO-C for their performance and for their short- and medium-term safety. These implants will be placed using specific instruments, by oral or cranio-maxillofacial surgeons with significant experience in the placement of zygomatic implants and trained in clinical research.

Study design: Interventional pivotal study involving humans, prospective with continuous series, multicentre, European, open-label, non-comparative.

Clinical investigation classification: class 2 clinical investigation according to ANSM in France, aiming at establishing the conformity of a class IIb, non CE-marked medical device. Clinical investigation to demonstrate device compliance, in accordance with Article 62.1 of the MDR.

Investigators: Patient recruitment and follow-up will be carried out by dental surgeons or oral surgeons/stomatologists in France and Italy. 11 sites will participate in the CI in 2 countries (Italy and France).

Objective: To assess the performance of the ZygoFixU implant-prosthetic system by measuring the survival rate at 1 year postoperatively.

Population: Adult male or female patients, whose growth and development of the maxillary bone is complete, partially or completely edentulous with advanced atrophy of the maxillary bone (grades IV, V and VI according to the Cawood and Howell classification if used).

Inclusion Criteria:

• Adult male or female patient,
• Patient whose growth and development of the maxillary bone is complete according to the investigator's judgement,
• Partially or completely edentulous patient,
• Patient with advanced maxillary atrophy (grades IV, V and VI according to the Cawood and Howell classification if used),
• Patient requiring implant treatment with Global D zygomatic implants (placement of two or four implants),
• Patient with acceptable oral opening (>3 cm measured anteriorly),
• Patient able to read, understand and answer the quality-of-life questionnaire of the investigation and able to give consent,
• Patient agreeing to comply with the protocol design and to send his/her follow-up data, even in the event of a move,
• Patient having signed the consent form,
• In France, patient affiliated to a social security scheme.

Exclusion Criteria:

• Patient's state of health at enrolment:

  • General contraindications to implant surgery
  • Patient with zygomatic bone disease
  • Patient with untreated periodontal disease
  • Patient with acute or chronic infection in the implant placement area, or systemic infection, including acute or chronic maxillary sinusitis
  • Patient with acute or chronic inflammation in the implant placement area, or systemic inflammation,
  • Patient with uncontrolled diabetes (unstable blood glucose)
  • Patient with immunodeficiencies or using immunosuppressants
  • Patient who received radiation of more than +70 Gy to the head and neck region
  • Patient using intravenous aminobisphosphonates within 5 years prior to surgery

• Patient who are smokers (>10 cigarettes/day) or with alcohol or drug addiction

• Person placed under legal protection (this includes guardianship, curatorship and legal protection).

• Pregnant or breastfeeding women